세계의 T세포 림프종 시장 규모, 점유율 및 동향 분석 : 유형별, 치료법별, 지역별, 전망 및 예측(2024-2031년)

The Global T-cell Lymphoma Market size is expected to reach $3.7 billion by 2031, rising at a market growth of 8.5% CAGR during the forecast period.

There is a noticeable increase in the incidence of these lymphomas across various countries in the Asia-Pacific region. This rise can be attributed to changing demographics, environmental factors, lifestyle changes, and improved diagnostic capabilities, leading to better detection and reporting. Consequently, the Asia Pacific region would acquire nearly 28% of the total market share by 2031.

Improved understanding of these lymphomas among healthcare professionals leads to earlier disease detection. In addition, advances in diagnostic technologies, such as molecular profiling, flow cytometry, and imaging techniques, enhance the accuracy and reliability of these lymphoma diagnosis. Therefore, increasing disease awareness and diagnosis is driving the market's growth. Additionally, Higher healthcare expenditure typically leads to improved access to healthcare services, including diagnostic tests, specialist consultations, and advanced treatment options for these lymphomas. Furthermore, much healthcare spending goes towards oncology research and development (R&D), including these lymphomas. Thus, rising healthcare expenditure globally is propelling the growth of the market.

However, Advanced treatment modalities for these lymphomas, such as targeted therapies, immunotherapies, and stem cell transplants, are often costly to develop, manufacture, and administer. High treatment costs can create barriers to market access for pharmaceutical companies developing new therapies for these lymphomas. In conclusion, the high cost of treatment and healthcare services hinders the market's growth.

Restrictions on in-person visits, prioritization of COVID-19 trials, and logistical challenges hindered the progress of research and development efforts. Disruptions in global supply chains affected the availability of essential medications, supportive care therapies, and medical supplies needed to treat T-cell lymphomas. This posed challenges in maintaining continuity of care for patients. Economic uncertainties and healthcare resource reallocations during the pandemic strained healthcare systems and patients' financial resources. Access to specialized care and expensive treatments for T-cell lymphomas may have been limited, exacerbating disparities in healthcare access. Thus, the COVID-19 pandemic had a negative impact on the market.

Type Outlook

Based on type, the T-cell lymphoma market is divided into peripheral and lymphoblastic. In 2023, the lymphoblastic segment attained 35% revenue share in the T-cell lymphoma Market. T-cell lymphomas, including T-cell acute lymphoblastic leukemia (T-ALL), are relatively rare but often aggressive cancers. Their rapid progression and severity necessitate prompt and effective treatment, increasing the demand for specific therapies.

Therapy Outlook

On the basis of therapy, the market is segmented into radiotherapy, chemotherapy, immunotherapy, stem cell transplantation, and others. In 2023, the radiotherapy segment attained a 26% revenue share in the market. Radiotherapy treats localized lymphomas by delivering high-energy radiation directly to the tumor site.

By Regional Analysis

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region witnessed 39% revenue share in the market in 2023. North America, particularly the United States and Canada, has one of the highest healthcare expenditures globally. This allows for greater affordability and accessibility to advanced diagnostic tools, treatments, and therapies for T-cell lymphomas.

List of Key Companies Profiled

• Bristol Myers Squibb Company
• Daiichi Sankyo Company, Limited
• Eisai Co., Ltd
• Acrotech Biopharma Inc. (Aurobindo Pharma USA)
• Shenzhen Chipscreen Biosciences Co., Ltd.
• Citius Pharmaceuticals, Inc.
• Genor Biopharma Co. Ltd.
• Innate Pharma SA
• Dizal Pharmaceutical Co. Ltd.

Global T-cell Lymphoma Market Report Segmentation

By Type

• Peripheral
  • Cutaneous T-cell Lymphoma
  • Anaplastic Large Cell Lymphoma
  • Angio-immuno-blastic T-cell Lymphoma
  • Others
• Lymphoblastic

By Therapy

• Chemotherapy
• Radiotherapy
• Immunotherapy
• Stem Cell Transplantation
• Others

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1. Market Scope & Methodology

• 1.1 Market Definition
• 1.2 Objectives
• 1.3 Market Scope
• 1.4 Segmentation
  • 1.4.1 Global T-cell Lymphoma Market, by Type
  • 1.4.2 Global T-cell Lymphoma Market, by Therapy
  • 1.4.3 Global T-cell Lymphoma Market, by Geography
• 1.5 Methodology for the research

Chapter 2. Market at a Glance

• 2.1 Key Highlights

Chapter 3. Market Overview

• 3.1 Introduction
  • 3.1.1 Overview
    • 3.1.1.1 Market Composition and Scenario
• 3.2 Key Factors Impacting the Market
  • 3.2.1 Market Drivers
  • 3.2.2 Market Restraints
  • 3.2.3 Market Opportunities
  • 3.2.4 Market Challenges
• 3.3 Porter Five Forces Analysis

Chapter 4. Global T-cell Lymphoma Market by Type

• 4.1 Global Peripheral Market by Region
• 4.2 Global T-cell Lymphoma Market by Peripheral Type
  • 4.2.1 Global Cutaneous T-cell Lymphoma Market by Region
  • 4.2.2 Global Anaplastic Large Cell Lymphoma Market by Region
  • 4.2.3 Global Angio-immuno-blastic T-cell Lymphoma Market by Region
  • 4.2.4 Global Others Market by Region
• 4.3 Global Lymphoblastic Market by Region

Chapter 5. Global T-cell Lymphoma Market by Therapy

• 5.1 Global Chemotherapy Market by Region
• 5.2 Global Radiotherapy Market by Region
• 5.3 Global Immunotherapy Market by Region
• 5.4 Global Stem Cell Transplantation Market by Region
• 5.5 Global Others Market by Region

Chapter 6. Global T-cell Lymphoma Market by Region

• 6.1 North America T-cell Lymphoma Market
  • 6.1.1 North America T-cell Lymphoma Market by Type
    • 6.1.1.1 North America Peripheral Market by Country
    • 6.1.1.2 North America T-cell Lymphoma Market by Peripheral Type
      • 6.1.1.2.1 North America Cutaneous T-cell Lymphoma Market by Country
      • 6.1.1.2.2 North America Anaplastic Large Cell Lymphoma Market by Country
      • 6.1.1.2.3 North America Angio-immuno-blastic T-cell Lymphoma Market by Country
      • 6.1.1.2.4 North America Others Market by Country
    • 6.1.1.3 North America Lymphoblastic Market by Country
  • 6.1.2 North America T-cell Lymphoma Market by Therapy
    • 6.1.2.1 North America Chemotherapy Market by Country
    • 6.1.2.2 North America Radiotherapy Market by Country
    • 6.1.2.3 North America Immunotherapy Market by Country
    • 6.1.2.4 North America Stem Cell Transplantation Market by Country
    • 6.1.2.5 North America Others Market by Country
  • 6.1.3 North America T-cell Lymphoma Market by Country
    • 6.1.3.1 US T-cell Lymphoma Market
      • 6.1.3.1.1 US T-cell Lymphoma Market by Type
      • 6.1.3.1.2 US T-cell Lymphoma Market by Therapy
    • 6.1.3.2 Canada T-cell Lymphoma Market
      • 6.1.3.2.1 Canada T-cell Lymphoma Market by Type
      • 6.1.3.2.2 Canada T-cell Lymphoma Market by Therapy
    • 6.1.3.3 Mexico T-cell Lymphoma Market
      • 6.1.3.3.1 Mexico T-cell Lymphoma Market by Type
      • 6.1.3.3.2 Mexico T-cell Lymphoma Market by Therapy
    • 6.1.3.4 Rest of North America T-cell Lymphoma Market
      • 6.1.3.4.1 Rest of North America T-cell Lymphoma Market by Type
      • 6.1.3.4.2 Rest of North America T-cell Lymphoma Market by Therapy
• 6.2 Europe T-cell Lymphoma Market
  • 6.2.1 Europe T-cell Lymphoma Market by Type
    • 6.2.1.1 Europe Peripheral Market by Country
    • 6.2.1.2 Europe T-cell Lymphoma Market by Peripheral Type
      • 6.2.1.2.1 Europe Cutaneous T-cell Lymphoma Market by Country
      • 6.2.1.2.2 Europe Anaplastic Large Cell Lymphoma Market by Country
      • 6.2.1.2.3 Europe Angio-immuno-blastic T-cell Lymphoma Market by Country
      • 6.2.1.2.4 Europe Others Market by Country
    • 6.2.1.3 Europe Lymphoblastic Market by Country
  • 6.2.2 Europe T-cell Lymphoma Market by Therapy
    • 6.2.2.1 Europe Chemotherapy Market by Country
    • 6.2.2.2 Europe Radiotherapy Market by Country
    • 6.2.2.3 Europe Immunotherapy Market by Country
    • 6.2.2.4 Europe Stem Cell Transplantation Market by Country
    • 6.2.2.5 Europe Others Market by Country
  • 6.2.3 Europe T-cell Lymphoma Market by Country
    • 6.2.3.1 Germany T-cell Lymphoma Market
      • 6.2.3.1.1 Germany T-cell Lymphoma Market by Type
      • 6.2.3.1.2 Germany T-cell Lymphoma Market by Therapy
    • 6.2.3.2 UK T-cell Lymphoma Market
      • 6.2.3.2.1 UK T-cell Lymphoma Market by Type
      • 6.2.3.2.2 UK T-cell Lymphoma Market by Therapy
    • 6.2.3.3 France T-cell Lymphoma Market
      • 6.2.3.3.1 France T-cell Lymphoma Market by Type
      • 6.2.3.3.2 France T-cell Lymphoma Market by Therapy
    • 6.2.3.4 Russia T-cell Lymphoma Market
      • 6.2.3.4.1 Russia T-cell Lymphoma Market by Type
      • 6.2.3.4.2 Russia T-cell Lymphoma Market by Therapy
    • 6.2.3.5 Spain T-cell Lymphoma Market
      • 6.2.3.5.1 Spain T-cell Lymphoma Market by Type
      • 6.2.3.5.2 Spain T-cell Lymphoma Market by Therapy
    • 6.2.3.6 Italy T-cell Lymphoma Market
      • 6.2.3.6.1 Italy T-cell Lymphoma Market by Type
      • 6.2.3.6.2 Italy T-cell Lymphoma Market by Therapy
    • 6.2.3.7 Rest of Europe T-cell Lymphoma Market
      • 6.2.3.7.1 Rest of Europe T-cell Lymphoma Market by Type
      • 6.2.3.7.2 Rest of Europe T-cell Lymphoma Market by Therapy
• 6.3 Asia Pacific T-cell Lymphoma Market
  • 6.3.1 Asia Pacific T-cell Lymphoma Market by Type
    • 6.3.1.1 Asia Pacific Peripheral Market by Country
    • 6.3.1.2 Asia Pacific T-cell Lymphoma Market by Peripheral Type
      • 6.3.1.2.1 Asia Pacific Cutaneous T-cell Lymphoma Market by Country
      • 6.3.1.2.2 Asia Pacific Anaplastic Large Cell Lymphoma Market by Country
      • 6.3.1.2.3 Asia Pacific Angio-immuno-blastic T-cell Lymphoma Market by Country
      • 6.3.1.2.4 Asia Pacific Others Market by Country
    • 6.3.1.3 Asia Pacific Lymphoblastic Market by Country
  • 6.3.2 Asia Pacific T-cell Lymphoma Market by Therapy
    • 6.3.2.1 Asia Pacific Chemotherapy Market by Country
    • 6.3.2.2 Asia Pacific Radiotherapy Market by Country
    • 6.3.2.3 Asia Pacific Immunotherapy Market by Country
    • 6.3.2.4 Asia Pacific Stem Cell Transplantation Market by Country
    • 6.3.2.5 Asia Pacific Others Market by Country
  • 6.3.3 Asia Pacific T-cell Lymphoma Market by Country
    • 6.3.3.1 China T-cell Lymphoma Market
      • 6.3.3.1.1 China T-cell Lymphoma Market by Type
      • 6.3.3.1.2 China T-cell Lymphoma Market by Therapy
    • 6.3.3.2 Japan T-cell Lymphoma Market
      • 6.3.3.2.1 Japan T-cell Lymphoma Market by Type
      • 6.3.3.2.2 Japan T-cell Lymphoma Market by Therapy
    • 6.3.3.3 India T-cell Lymphoma Market
      • 6.3.3.3.1 India T-cell Lymphoma Market by Type
      • 6.3.3.3.2 India T-cell Lymphoma Market by Therapy
    • 6.3.3.4 South Korea T-cell Lymphoma Market
      • 6.3.3.4.1 South Korea T-cell Lymphoma Market by Type
      • 6.3.3.4.2 South Korea T-cell Lymphoma Market by Therapy
    • 6.3.3.5 Singapore T-cell Lymphoma Market
      • 6.3.3.5.1 Singapore T-cell Lymphoma Market by Type
      • 6.3.3.5.2 Singapore T-cell Lymphoma Market by Therapy
    • 6.3.3.6 Malaysia T-cell Lymphoma Market
      • 6.3.3.6.1 Malaysia T-cell Lymphoma Market by Type
      • 6.3.3.6.2 Malaysia T-cell Lymphoma Market by Therapy
    • 6.3.3.7 Rest of Asia Pacific T-cell Lymphoma Market
      • 6.3.3.7.1 Rest of Asia Pacific T-cell Lymphoma Market by Type
      • 6.3.3.7.2 Rest of Asia Pacific T-cell Lymphoma Market by Therapy
• 6.4 LAMEA T-cell Lymphoma Market
  • 6.4.1 LAMEA T-cell Lymphoma Market by Type
    • 6.4.1.1 LAMEA Peripheral Market by Country
    • 6.4.1.2 LAMEA T-cell Lymphoma Market by Peripheral Type
      • 6.4.1.2.1 LAMEA Cutaneous T-cell Lymphoma Market by Country
      • 6.4.1.2.2 LAMEA Anaplastic Large Cell Lymphoma Market by Country
      • 6.4.1.2.3 LAMEA Angio-immuno-blastic T-cell Lymphoma Market by Country
      • 6.4.1.2.4 LAMEA Others Market by Country
    • 6.4.1.3 LAMEA Lymphoblastic Market by Country
  • 6.4.2 LAMEA T-cell Lymphoma Market by Therapy
    • 6.4.2.1 LAMEA Chemotherapy Market by Country
    • 6.4.2.2 LAMEA Radiotherapy Market by Country
    • 6.4.2.3 LAMEA Immunotherapy Market by Country
    • 6.4.2.4 LAMEA Stem Cell Transplantation Market by Country
    • 6.4.2.5 LAMEA Others Market by Country
  • 6.4.3 LAMEA T-cell Lymphoma Market by Country
    • 6.4.3.1 Brazil T-cell Lymphoma Market
      • 6.4.3.1.1 Brazil T-cell Lymphoma Market by Type
      • 6.4.3.1.2 Brazil T-cell Lymphoma Market by Therapy
    • 6.4.3.2 Argentina T-cell Lymphoma Market
      • 6.4.3.2.1 Argentina T-cell Lymphoma Market by Type
      • 6.4.3.2.2 Argentina T-cell Lymphoma Market by Therapy
    • 6.4.3.3 UAE T-cell Lymphoma Market
      • 6.4.3.3.1 UAE T-cell Lymphoma Market by Type
      • 6.4.3.3.2 UAE T-cell Lymphoma Market by Therapy
    • 6.4.3.4 Saudi Arabia T-cell Lymphoma Market
      • 6.4.3.4.1 Saudi Arabia T-cell Lymphoma Market by Type
      • 6.4.3.4.2 Saudi Arabia T-cell Lymphoma Market by Therapy
    • 6.4.3.5 South Africa T-cell Lymphoma Market
      • 6.4.3.5.1 South Africa T-cell Lymphoma Market by Type
      • 6.4.3.5.2 South Africa T-cell Lymphoma Market by Therapy
    • 6.4.3.6 Nigeria T-cell Lymphoma Market
      • 6.4.3.6.1 Nigeria T-cell Lymphoma Market by Type
      • 6.4.3.6.2 Nigeria T-cell Lymphoma Market by Therapy
    • 6.4.3.7 Rest of LAMEA T-cell Lymphoma Market
      • 6.4.3.7.1 Rest of LAMEA T-cell Lymphoma Market by Type
      • 6.4.3.7.2 Rest of LAMEA T-cell Lymphoma Market by Therapy

Chapter 7. Company Profiles

• 7.1 Bristol Myers Squibb Company
  • 7.1.1 Company Overview
  • 7.1.2 SWOT Analysis
• 7.2 Daiichi Sankyo Company, Limited
  • 7.2.1 Company Overview
  • 7.2.2 SWOT Analysis
• 7.3 Eisai Co., Ltd.
  • 7.3.1 Company Overview
  • 7.3.2 Financial Analysis
  • 7.3.3 Segmental and Regional Analysis
  • 7.3.4 Research & Development Expenses
  • 7.3.5 SWOT Analysis
• 7.4 Acrotech Biopharma Inc. (Aurobindo Pharma USA)
  • 7.4.1 Company Overview
• 7.5 Shenzhen Chipscreen Biosciences Co., Ltd.
  • 7.5.1 Company Overview
• 7.6 Citius Pharmaceuticals, Inc.
  • 7.6.1 Company Overview
  • 7.6.2 Recent strategies and developments:
    • 7.6.2.1 Trials and Approvals:
• 7.7 Genor Biopharma Co. Ltd
  • 7.7.1 Company Overview
  • 7.7.2 Financial Analysis
  • 7.7.3 Research & Development Expenses
• 7.8 Innate Pharma SA
  • 7.8.1 Company Overview
  • 7.8.2 Financial Analysis
  • 7.8.3 Research & Development Expenses
• 7.9 Dizal Pharmaceutical Co. Ltd.
  • 7.9.1 Company Overview
  • 7.9.2 Recent strategies and developments:
    • 7.9.2.1 Trials and Approvals:

Chapter 8. Winning imperatives for T-cell Lymphoma Market